Developing small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases.
Developing 'best in class' small molecule drugs for Type II diabetes and Osteoarthritis/inflammation based diseases. Apart from the lead product (DPPIV inhibitor in phase I clinical trials) Alantos had 5 programs in various stages of preclinical development.
Alantos Pharmaceuticals was acquired by Amgen in 2007 for US$ 300 million.
Human Health
Industry
Biotech
Status
Realised
Location
Germany